Vol 26, No 4 (2021)
Research paper
Published online: 2021-03-26

open access

Page views 578
Article views/downloads 360
Get Citation

Connect on Social Media

Connect on Social Media

Role of whole brain radiotherapy in the management of infratentorial metastases from lung and breast cancer

Bernardo Cacho-Díaz1, Alejandra Alvarez-Alvarez1, Karen Salmerón-Moreno1, Oscar Rodríguez-Mayoral2, Bernardino Gabriel Santiago-Concha3, Oscar G. Arrieta Rodríguez4
Rep Pract Oncol Radiother 2021;26(4):512-517.


BACKGROUND: Brain metastases (BM) occur in almost one third of patients with systemic malignancies. Only a small number of studies focus on infratentorial location and whole brain radiotherapy (WBRT) as the main non-surgical management.

The aim of the study was to compare the prognosis of patients treated with WBRT among patients with supra- or infratentorial lesions.

MATERIALS AND METHODS: At a single center, 263 patients with either breast (BC) or lung (LC) cancer, that had developed BM and received treatment with WBRT, were analyzed during an 8-year period.

RESULTS: A total of 152 patients with BC and 111 with LC were analyzed, median age at the time of BM was 50.7 years, systemic activity other than BM was detected in 91%. Newly diagnosed BM were supratentorial in 40%, infratentorial in 10% and 51% in both locations. Median overall survival was 13 months (95% CI: 11.1–14.8 months), without significant difference between supra- or infratentorial location. WBRT alone was administered in 79% of patients, whereas WBRT with chemtoreapy was provided for 21%.

CONCLUSION: In patients with BM from LC or BC that were not candidates for surgical resection, palliative WBRT appears to be equally effective in those with supra- or infratentorial locations.

Article available in PDF format

View PDF Download PDF file


  1. Gállego Pérez-Larraya J, Hildebrand J. Brain metastases. Handb Clin Neurol. 2014; 121: 1143–1157.
  2. Suh JH, Kotecha R, Chao ST, et al. Current approaches to the management of brain metastases. Nat Rev Clin Oncol. 2020; 17(5): 279–299.
  3. Moravan MJ, Fecci PE, Anders CK, et al. Current multidisciplinary management of brain metastases. Cancer. 2020; 126(7): 1390–1406.
  4. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012; 14(1): 48–54.
  5. Kancharla P, Ivanov A, Chan S, et al. The effect of brain metastasis location on clinical outcomes: A review of the literature. Neurooncol Adv. 2019; 1(1): vdz017.
  6. Sunderland GJ, Jenkinson MD, Zakaria R. Surgical management of posterior fossa metastases. J Neurooncol. 2016; 130(3): 535–542.
  7. Tsao MN, Xu W, Wong RKs, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2018; 1: CD003869.
  8. Arrieta O, Villarreal-Garza C, Zamora J, et al. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol. 2011; 6: 166.
  9. Sato Y, Yamamoto M, Serizawa T, et al. Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors. J Neurosurg. 2014; 121 Suppl(3): 16–25.
  10. Qie S, Li Y, Shi HY, et al. Stereotactic radiosurgery (SRS) alone versus whole brain radiotherapy plus SRS in patients with 1 to 4 brain metastases from non-small cell lung cancer stratified by the graded prognostic assessment: A meta-analysis (PRISMA) of randomized control trials. Medicine (Baltimore). 2018; 97(33): e11777.
  11. Nicosia L, Figlia V, Mazzola R, et al. Repeated stereotactic radiosurgery (SRS) using a non-coplanar mono-isocenter (HyperArc™) technique versus upfront whole-brain radiotherapy (WBRT): a matched-pair analysis. Clin Exp Metastasis. 2020; 37(1): 77–83.
  12. Bender ET, Tomé WA. Distribution of brain metastases: implications for non-uniform dose prescriptions. Br J Radiol. 2011; 84(1003): 649–658.